First Tracks Biotherapeutics, Inc. (TRAX) is currently trading at $48.7 with a Wall Street consensus price target of $75.17, implying potential upside of 54.3% over the next 12 months. 12 analysts currently cover TRAX, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $110.0, while the most cautious has a target of $57.0.
TRAX operates in the Healthcare sector with a market capitalisation of $2B. The stock is up 0.0% year-to-date and is currently trading near the upper end of its 52-week range of $14.72 – $54.78.
Other Healthcare stocks with comparable size and valuation.
Upgrade/downgrade history for TRAX, with each firm's 90-day track record across all stocks we track. See full firm rankings →
Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.
Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.
StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.
View Full Rankings →